Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex launches new high throughput laboratory in its US facility

Cyprotex launches new high throughput laboratory in its US facility

31st March, 2015; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announced today the launch of a new high throughput screening laboratory at its US facility in Watertown near Boston. The laboratory replicates the highly successful ADME screening laboratory in Cyprotex’s UK facility which has been developed in-house over the past 16 years using the combined expertise of our skilled software engineers and scientists. The unique platform allows Cyprotex to provide services which generate high quality consistent data in a rapid and cost-effective manner. All our customers, large and small, have access to and can benefit from the services available in North America.

The new facility houses state of the art automated liquid handling instruments and LC-MS/MS analytical instruments as well as a team of scientists and software engineers who are experienced in the field of high throughput screening. The integration has been led by our UK team who have been responsible for training staff and managing the smooth transfer of existing procedures and cross validation of the assays.

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “Expansion of our high throughput screening facility to the US has always been a much desired part of our growth strategy plans. Our unique software platform combined with state of the art automation and bioanalytical capabilities make us one of the only contract research facilities to be able to screen such large numbers of compounds in such a wide range of assays with relative ease. The medium and large Pharmaceutical companies who require high capacity and high quality screening with short turnaround times are realising the benefit of working with Cyprotex and as such the number of strategic deals are increasing and are a key factor in the growth of our business.”

For Further Information:

Cyprotex PLC 

Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@n1singer.com
Jen Boorer
jennifer.boorer@n1singer.com
www.nplus1singer.com

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries.  The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close